These findings correlated with Western Blot analysis of the isolated tumor tissue, which showed reduced levels of Mcl-1, in both the seliciclib-only treated animals and the animals treated with seliciclib plus drozitumab (Figure 4b). Here, MCL1 is linked to neoplasm.